Elevated levels of MYC are frequently linked to increased tumor aggressiveness and worse clinical outcomes [26], particularly in two of the four subtypes: ERMS, which shows lower levels of MYC, and ARMS, the subtype characterized by the highest MYC levels [27]. This evidence concerns the gene MYC and neoplasm.